Literature DB >> 21412703

Post-ERCP pancreatitis in 2364 ERCP procedures: is intraductal ultrasonography another risk factor?

T Meister1, H Heinzow, A Heinecke, R Hoehr, W Domschke, D Domagk.   

Abstract

BACKGROUND AND STUDY AIMS: Acute pancreatitis is considered a relevant major complication following endoscopic retrograde cholangiopancreatography (ERCP); according to literature data, the incidence varies between 1.5 % and 17 %. In the present study, we aimed to identify potentially new, hitherto unknown risk factors for post-ERCP pancreatitis. PATIENTS AND METHODS: A total of 2364 ERCP procedures performed in 1275 patients during the years 2004 - 2008 were included in the study. Post-ERCP pancreatitis was defined as acute abdominal pain within 48 hours following ERCP with at least 3-fold elevated levels of serum lipase and a requirement for analgesic drugs for at least 24 hours. The severity of the pancreatitis was determined using the Imrie score.
RESULTS: In our cohort study a total of 54 different patients (2.3 %) developed post-ERCP pancreatitis. In 50 of these patients (92.6 %) the pancreatitis was mild; in 54 (7.4 %) it was severe. Patients with post-ERCP pancreatitis had highly significantly lower bilirubin levels than patients who did not have post-ERCP pancreatitis ( P < 0.001). Length of hospital stay, duration of analgesics, and need for analgesic drugs were significantly higher in patients suffering from severe pancreatitis ( P ≤ 0.01). In multivariate analysis, among other, already well-described risk factors we identified intraductal ultrasonography as another risk factor for post-ERCP pancreatitis, with a hazard ratio of 2.41 ( P = 0.004).
CONCLUSIONS: According to our retrospective data, intraductal ultrasonography seems to be another independent risk factor for developing post-ERCP pancreatitis, which needs to be further elucidated in prospective studies. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21412703     DOI: 10.1055/s-0030-1256194

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  10 in total

1.  EUS-guided FNA for biliary disease as first-line modality to obtain histological evidence.

Authors:  Saori Onda; Takeshi Ogura; Yoshitaka Kurisu; Daisuke Masuda; Tatsushi Sano; Wataru Takagi; Shinya Fukunishi; Kazuhide Higuchi
Journal:  Therap Adv Gastroenterol       Date:  2016-02-11       Impact factor: 4.409

2.  Systematic pancreatic stenting after endoscopic snare papillectomy may reduce the risk of postinterventional pancreatitis.

Authors:  Bertrand Napoléon; M Victoria Alvarez-Sanchez; Philippe Leclercq; François Mion; Jean Pialat; Rodica Gincul; Daniel Ribeiro; Marie Cambou; Christine Lefort; Mar Rodríguez-Girondo; Jean Yves Scoazec
Journal:  Surg Endosc       Date:  2013-04-03       Impact factor: 4.584

3.  Comparative analysis of ERCP, IDUS, EUS and CT in predicting malignant bile duct strictures.

Authors:  Hauke S Heinzow; Sara Kammerer; Carina Rammes; Johannes Wessling; Dirk Domagk; Tobias Meister
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

4.  Endoscopic sphincterotomy and endoscopic biliary stenting do not affect the sensitivity of transpapillary forceps biopsy for the diagnosis of bile duct adenocarcinoma.

Authors:  Toshinori Aoki; Eizaburo Ohno; Takuya Ishikawa; Yasuyuki Mizutani; Tadashi Iida; Kentaro Yamao; Takeshi Yamamura; Kazuhiro Furukawa; Masanao Nakamura; Takashi Honda; Masatoshi Ishigami; Hiroshi Yatsuya; Hiroki Kawashima
Journal:  BMC Gastroenterol       Date:  2022-07-05       Impact factor: 2.847

Review 5.  Prevention of post-ERCP pancreatitis.

Authors:  Jennifer Maranki; Paul Yeaton
Journal:  Curr Gastroenterol Rep       Date:  2013-11

6.  The modified pancreatic stent system for prevention of post-ERCP pancreatitis: a case-control study.

Authors:  Cheng Zhang; Yu-Long Yang; Yue-Feng Ma; Hong-Wei Zhang; Jing-Yi Li; Mei-Ju Lin; Li-Jun Shi; Chun-Chun Qi
Journal:  BMC Gastroenterol       Date:  2017-10-18       Impact factor: 3.067

7.  Dilatation Therapy and Demographic Characteristics Significantly Influence the Amount of Propofol for Therapeutic Endoscopic Retrograde Cholangiography.

Authors:  Christoph A Schmidt; Carsten Keil; Martha M Kirstein; Frank Lehner; Michael P Manns; Thomas von Hahn; Tim O Lankisch; Torsten Voigtländer
Journal:  Int J Hepatol       Date:  2019-07-01

8.  New practical scoring system to predict post-endoscopic retrograde cholangiopancreatography pancreatitis: Development and validation.

Authors:  Koichi Fujita; Shujiro Yazumi; Norimitsu Uza; Akira Kurita; Masanori Asada; Yuzo Kodama; Masashi Goto; Toshiro Katayama; Takahiro Anami; Akihiko Watanabe; Atsushi Sugahara; Hidekazu Mukai; Takashi Kawamura
Journal:  JGH Open       Date:  2021-08-12

9.  Safety, diagnostic accuracy and therapeutic efficacy of digital single-operator cholangioscopy.

Authors:  Frank Lenze; Arne Bokemeyer; Dina Gross; Tobias Nowacki; Dominik Bettenworth; Hansjoerg Ullerich
Journal:  United European Gastroenterol J       Date:  2018-03-08       Impact factor: 4.623

10.  Post-endoscopic retrograde cholangiopancreatography pancreatitis assessed using criteria for acute pancreatitis.

Authors:  Azumi Suzuki; Koji Uno; Kojiro Nakase; Koichiro Mandai; Bunji Endoh; Koki Chikugo; Takumi Kawakami; Takahiro Suzuki; Yoshitaka Nakai; Kiyonori Kusumoto; Yoshio Itokawa; Osamu Inatomi; Shigeki Bamba; Yoshinori Mizumoto; Kiyohito Tanaka
Journal:  JGH Open       Date:  2021-12-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.